NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Anti-cancer systemic therapy programme under pressure

By Paul Mulholland - 06th Dec 2021

In a hospital room, an asian female cancer patient is chatting with her doctor. Both of them are wearing a mask during the coronavirus pandemic to help prevent the transfer of germs. The doctor is a female and of African American ethnicity.

A number of major issues were identified regarding the operation of the systemic therapy programme at the meeting of the National Cancer Control Programme’s (NCCP) executive management team in September. According to the minutes of the meeting, released to the Medical Independent through Freedom of Information, work was ongoing on seeking “a short- to medium-term resolution to systemic anti-cancer therapy treatment capacity and waiting lists”.

There was also a backlog in the drugs approval process, with the HSE drugs group due to meet on the issue. “The cyberattack has impacted on the cytogenetics testing service,” according to the minutes. “All adult cytogenetics, bar CLL [chronic lymphocytic leukaemia], are now being outsourced.”

St James’s Hospital, Dublin, and Children’s Health Ireland at Crumlin were to revert with a proposed job description for a cytogenetics oversight post in the near future. The cyberattack was also continuing to have an impact with “notable data gaps” and paper records still to be uploaded to patient files. The July meeting had heard that “clinical risk” as a result of the cyberattack was still an issue.

“[D]ata availability, which informs decision making is intermittent,” the minutes state. “MDMs [multidisciplinary meetings] continue to run in the absence of data, or with limited data.” In July, continuing problems were noted regarding the recruitment of appropriately trained staff.

“It is difficult to get staff who are appropriately trained,” according to the minutes. “Funding does not always solve the
problem where there is a shortage of appropriately trained staff. This may impact on the delivery of clinical trials in the west of Ireland.”

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read